ADAPTIVE BIOTECHNOLOGIES CORPORATION — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1baade38-9d49-4977-af0e-98cd612e595a/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $277.0M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-076902 |
| FY 2024 | $179.0M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-030913 |
| FY 2023 | $170.3M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-023095 |
| FY 2022 | $185.3M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-002792 |
| FY 2021 | $154.3M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-005228 |
| FY 2020 | $98.4M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-008124 |
| FY 2019 | $85.1M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-006830 |
| FY 2018 | $55.7M | 2018-01-01 – 2018-12-31 | evidence 0001564590-20-006830 |
| FY 2017 | $38.4M | 2017-01-01 – 2017-12-31 | evidence 0001564590-20-006830 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ADAPTIVE BIOTECHNOLOGIES CORPORATION — all facts · Net Income · Operating Income